{
  "ticker": "GLO",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961147",
  "id": "02961147",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1737",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0sd1lmwzc1x.pdf",
  "summary": "### **Summary of ASX Announcement \u2013 Barrow Hanley Global Share Active ETF (ASX: GLOB)**  \n\n#### **Material Information:**  \n- **Performance (31 May 2025):**  \n  - 1-month return: **2.79%** (vs. benchmark **5.31%**)  \n  - 1-year return: **15.63%** (vs. benchmark **17.52%**)  \n  - Underperformance driven by **underweights in IT & Communications Services** and **overweight to Real Estate**.  \n\n- **Top Holdings (Sector Allocation):**  \n  - **Bank of Nova Scotia (3.0%)**, **Sanofi SA (3.0%)**, **Merck & Co. (2.9%)**, **Rheinmetall AG (2.8%)**, **BAE Systems (2.5%)**.  \n  - Largest sector exposures: **Financials Ex-Property (18.7%), Industrials (14.0%), Healthcare (10.8%)**.  \n\n- **Regional Allocation:**  \n  - **North America (55.4%)**, **Europe ex-UK (20.1%)**, **Emerging Markets (2.9%)**, **Cash (3.5%)**.  \n\n- **Key Stock Developments:**  \n  - **Rheinmetall AG (+):** Strong defense sales growth (+73% YoY), backlog at **\u20ac62B**, new JV with Lockheed.  \n  - **Carnival Corp (+):** Debt refinancing saves **$20M/year** in interest costs amid lower oil prices.  \n  - **Merck & Co. (\u2013):** Regulatory risks (Keytruda pricing, biosimilar competition by 2028), halted China shipments.  \n  - **Sanofi (\u2013):** Mixed pipeline results, **$9B acquisition** of Blueprint Medicines.  \n\n- **Market Outlook:**  \n  - Ongoing volatility from **geopolitical risks (tariffs, elections, trade disputes)**.  \n  - Fed rate cuts remain uncertain amid strong economic data.  \n\n#### **Non-Material (Omitted):**  \n- Boilerplate disclaimers, generic risks, distribution frequency, management fee.  \n\n### **Conclusion:**  \nUnderperformance vs. benchmark, key stock-specific drivers (Rheinmetall, Merck, Sanofi), and macro risks (tariffs, Fed policy) are the primary material considerations.",
  "usage": {
    "prompt_tokens": 2503,
    "completion_tokens": 506,
    "total_tokens": 3009,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T08:50:04.562575"
}